Remedium Lifecare Ltd. , a prominent player in the pharmaceutical supply chain and specialty chemicals sector, has announced significant changes to its leadership team. The company has appointed Mr. Vignesh Laxman Gawde as Whole-Time Director and Mr. Rambhajan Vishwakarma as Independent Director, in a move aimed at enhancing its leadership and promoting growth in the pharmaceutical sector.

Strategic Appointments

The appointments come at a crucial time for Remedium Lifecare as it seeks to accelerate its growth momentum. Mr. Adarsh Munjal, Managing Director of Remedium Lifecare Ltd., expressed confidence in the new appointments, stating, "Mr. Gawde's deep technical expertise in the pharmaceutical field and Mr. Vishwakarma's vast experience in the financial sector will bring a strong strategic balance to our leadership team."

Expertise and Experience

Mr. Gawde, with his extensive background in pharmaceutical research, is expected to focus on strengthening R&D, quality assurance, and innovation. His expertise aligns with Remedium Lifecare's expansion plans across key therapeutic areas, including anti-infectives, cardiovascular, and CNS treatments.

Mr. Vishwakarma's appointment as Independent Director is aimed at enhancing corporate governance, transparency, and financial oversight. His experience in the financial sector is expected to support Remedium Lifecare's financial prudence and growth strategy.

Future Outlook

These strategic appointments underscore Remedium Lifecare's commitment to building a robust, future-ready leadership structure. The company anticipates that the combined experience of Mr. Gawde and Mr. Vishwakarma will drive its next phase of expansion, enhancing R&D capabilities, strengthening operational efficiencies, and deepening market presence across domestic and global geographies.

As Remedium Lifecare continues to evolve in the pharmaceutical and specialty chemicals space, these leadership changes signal the company's focus on innovation, quality, and strategic growth. The company remains dedicated to developing and distributing advanced healthcare solutions, with a growing emphasis on R&D, CDMO services, and international expansion.

Remedium Lifecare Limited has announced significant changes to its board composition and committee structure, as per a recent filing with the BSE. The company's Board of Directors, in a meeting held on October 31, 2025, approved several key appointments and restructuring measures.

New Board Appointments

The company has made two notable appointments to its board:

1. Mr. Rambhajan Vishwakarma (DIN: 11360922) has been appointed as an Additional Director (Non-Executive, Non-Independent) and Chairman of the Board, effective October 31, 2025.
2. Mr. Vignesh Laxman Gawde (DIN: 11360925) has been appointed as an Additional Executive/Whole-time Director for a five-year term, also effective from October 31, 2025.

Both appointments are subject to shareholder approval within three months or at the next General Meeting, whichever is earlier.

Director Profiles

Board Committee Restructuring

The company has reconstituted four key committees:

1. Audit Committee: Now chaired by Mr. Vijay Pal Singh Gulya (Independent Director)
2. Nomination and Remuneration Committee: Chaired by Mrs. Shamim Adil Michal (Independent Director)
3. Stakeholders Relationship Committee: Chaired by Mr. Rambhajan Vishwakarma
4. Risk Management Committee: Chaired by Mrs. Shamim Adil Michal

It's worth noting that the Nomination and Remuneration Committee was dissolved prior to these appointments due to director resignations, which prevented their recommendation for the new appointments.

Postal Ballot and Other Approvals

The board has approved postal ballot notices for:

1. Change of the company name
2. Regularization of Mr. Rambhajan Vishwakarma's appointment
3. Regularization and remuneration approval for Mr. Vignesh Laxman Gawde

The e-voting for these resolutions is scheduled to conclude on December 7, 2025.

These changes mark a significant restructuring of Remedium Lifecare's leadership and governance structure, potentially signaling a new direction for the company's operations and strategy.